Reglagene Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 15

Reglagene General Information

Description

Operator of preclinical oncology therapeutics intended to treat brain metastases and other cancers affecting the central nervous system. The company offers an orally administered, brain-penetrant tubulin-destabilizing drug candidate in investigational new drug-enabling development, enabling pharmaceutical researchers and oncology clinicians to advance potential treatments for cancers affecting the brain and central nervous system.

Contact Information

Website
www.reglagene.com
Formerly Known As
Reglagene Holding
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 300 North Main Avenue
  • Suite 105
  • Tucson, AZ 85701
  • United States
+1 (520)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 300 North Main Avenue
  • Suite 105
  • Tucson, AZ 85701
  • United States
+1 (520)

Reglagene Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reglagene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 11-Jan-2026 Completed Pre-Clinical Trials
13. Accelerator/Incubator 22-Nov-2024 Completed Pre-Clinical Trials
12. Debt - General 21-May-2024 Completed Pre-Clinical Trials
11. Later Stage VC (Series A1) 21-Nov-2023 Completed Pre-Clinical Trials
10. Angel (individual) 10-Sep-2021 Completed Pre-Clinical Trials
9. Later Stage VC 04-Feb-2021 Completed Startup
8. Seed Round 30-Dec-2020 Completed Startup
7. Grant 01-Jan-2020 Completed Startup
6. Grant 05-Apr-2019 $400K Completed Startup
5. Grant 17-Sep-2018 $300K Completed Startup
To view Reglagene’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Reglagene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of preclinical oncology therapeutics intended to treat brain metastases and other cancers affecting the central
Drug Discovery
Tucson, AZ
8 As of 2026

Clarksville, MD
 

Miami, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reglagene Competitors (63)

One of Reglagene’s 63 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD
Veru Corporation Miami, FL
Annovis Bio Formerly VC-backed Malvern, PA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Iovance Biotherapeutics Corporation San Carlos, CA
You’re viewing 5 of 63 competitors. Get the full list »

Reglagene Patents

  • 17

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Reglagene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026043617-A1 Compounds and methods of use thereof for treatment of health conditions and drug screening Pending 21-Aug-2024
AU-2024229823-A1 Compositions and methods for making and using small molecules for the treatment of health conditions Active 28-Feb-2023
AU-2024229823-B2 Compositions and methods for making and using small molecules for the treatment of health conditions Active 28-Feb-2023
EP-4673130-A1 Compositions and methods for making and using small molecules for the treatment of health conditions Pending 28-Feb-2023
EP-4673130-A4 Compositions and methods for making and using small molecules for the treatment of health conditions Pending 28-Feb-2023 A61K31/5377
To view Reglagene’s complete patent history, request access »

Reglagene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reglagene Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tech Coast Venture Network Angel Group Minority
Viva BioInnovator Accelerator/Incubator Minority
Brain Tumour Research Novel Therapeutics Accelerator Accelerator/Incubator
TCA Venture Group Angel Group Minority
Angel (individual) Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

Reglagene FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process